Year: 2015
Type: review
Abstract: Sepsis, also known as septicemia, is one of the 10 leading causes of death worldwide. The rising tide of sepsis due to bacterial, fungal and viral infections cannot be stemmed by current antimicrobial therapies and supportive measures. New paradigms for the mechanism and resolution of sepsis and consequences for sepsis survivors are emerging. Consistent with Benjamin Franklin's dictum 'an ounce of prevention is worth a pound of cure', sepsis can be prevented by vaccinations against pneumococci and meningococci. Recently, the NIH NHLBI Panel redefined sepsis as 'severe endothelial dysfunction syndrome in response to intravascular and extravascular infections causing reversible or irreversible injury to the microcirculation responsible for multiple organ failure'. Microvascular endothelial injury underlies sepsis-associated hypotension, edema, disseminated intravascular coagulation, acute respiratory distress syndrome and acute kidney injury. Microbial genome products trigger 'genome wars' in sepsis that reprogram the human genome and culminate in a 'genomic storm' in blood and vascular cells. Sepsis can be averted experimentally by endothelial cytoprotection through targeting nuclear signaling that mediates inflammation and deranged metabolism. Endothelial 'rheostats' (e.g. inhibitors of NF-κB, A20 protein, CRADD/RAIDD protein and microRNAs) regulate endothelial signaling. Physiologic 'extinguishers' (e.g. suppressor of cytokine signaling 3) can be replenished through intracellular protein therapy. Lipid mediators (e.g. resolvin D1) hasten sepsis resolution. As sepsis cases rose from 387 330 in 1996 to 1.1 million in 2011, and are estimated to reach 2 million by 2020 in the US, mortality due to sepsis approaches that of heart attacks and exceeds deaths from stroke. More preventive vaccines and therapeutic measures are urgently needed.
DOI: 10.1111/jth.13061
Authors: J. Hawiger, R.A. Veach, J. Zienkiewicz
Institution: Vanderbilt University
Language: English
Field: Medicine
Domain: Health Sciences
Keywords: sepsis, sepsis prevention, endothelial dysfunction, NF-κB signaling, microRNA, SOCS3, resolvin D1, lipid mediators, pneumococcal vaccination, meningococcal vaccination, multiple organ failure, disseminated intravascular coagulation, acute kidney injury, acute respiratory distress syndrome, sepsis mortality
Open Access status: hybrid
Estimated APC paid: $3,750
Funders: Vanderbilt University, Vanderbilt University Medical Center, National Institutes of Health, Vanderbilt Diabetes Research and Training Center, Vanderbilt University Medical Center, National Institute on Alcohol Abuse and Alcoholism, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
Awards: SARM-Mediated Nuclear Signaling in Innate Immunity, Immunobiology of Blood and Vascular Systems Training Program, G2683268942, Intracellular Protein Therapy with SOCS1 to Inhibit Acute Lung Inflammation, Vanderbilt Mouse Metabolic Phenotyping Center, MINORITY PREDOCTORAL FELLOWSHIP PROGRAM, Intracellular Therapeutics for Inflammatory Liver Injury, Superantigen-Induced Vascular Injury and DIC, G5679716143, MOLECULAR MECHANISMS OF SEPTIC SHOCK, Harnessing B lymphocytes as Antigen-Specific Regulators of Islet Tolerance, The Vanderbilt Institute for Clinical and Translational Research (VICTR), Functional Genomics of Inflammation, Suppression of Inflammation by Intracellular Targeting of MyD88, Targeted Suppression of Cytokine Signaling in the Acute Phase Response, Molecular and Cellular Basis for Digestive Diseases, Cancer Center Support Grant
OpenAlex ID: W1825470131
